These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20629136)

  • 1. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
    Mizuno Y; Hasegawa K; Kondo T; Kuno S; Yamamoto M;
    Mov Disord; 2010 Jul; 25(10):1437-43. PubMed ID: 20629136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
    Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.
    Fernandez HH; Greeley DR; Zweig RM; Wojcieszek J; Mori A; Sussman NM;
    Parkinsonism Relat Disord; 2010 Jan; 16(1):16-20. PubMed ID: 19616987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.
    Eggert K; Squillacote D; Barone P; Dodel R; Katzenschlager R; Emre M; Lees AJ; Rascol O; Poewe W; Tolosa E; Trenkwalder C; Onofrj M; Stocchi F; Nappi G; Kostic V; Potic J; Ruzicka E; Oertel W;
    Mov Disord; 2010 May; 25(7):896-905. PubMed ID: 20461807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
    Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV
    Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
    Kondo T; Mizuno Y;
    Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
    Chen W; Wang H; Wei H; Gu S; Wei H
    J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I;
    Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
    Mizuno Y; Kondo T;
    Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
    Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
    J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.